Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma-Reference-Cited by-同舟云学术

Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma

Published:2017-11 Issue:11 Volume:17 Page:734-742
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Varga Gergely,Mikala Gábor,Kiss Katalin Piroska,Kosóczki Éva,Szabó Edit,Meggyesi Nóra,Balassa Katalin,Kövy Petra,Tegze Bálint,Szombath Gergely^ORCID,Tordai Attila,Andrikovics Hajnalka,Homolya László^ORCID,Masszi Tamás

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial;Harousseau;J Clin Oncol,2010

2. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;Richardson;N Engl J Med,2005

3. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma;San Miguel;N Engl J Med,2008

4. Molecular mechanisms of proteasome assembly;Murata;Nat Rev Mol Cell Biol,2009

5. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells;Hideshima;Blood,2009

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analytical screening of polymorphic variants of 20S proteasome genes when planning a study of pathogenetic effects of modification of NFKB1 post-translational processing;Fundamental and Clinical Medicine;2023-06-30

2. Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genes;Frontiers in Oncology;2023-06-07

3. Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction;Translational Oncology;2022-11

4. Comprehensive Analysis of the Expression and Prognosis for PSMBs in Clear Cell Renal Cell Carcinoma;2022-05-13

5. Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance;Molecules;2022-03-28